The Transition of Oncology Monoclonal Antibody Treatments from IV to Subcutaneous Administration

Monoclonal antibodies (mAbs) have revolutionized modern oncology by introducing highly targeted therapeutic strategies that selectively attack cancer cells while minimizing damage to healthy tissues. Since their integration into cancer treatment protocols in the late 20th century, monoclonal antibodies have significantly improved survival outcomes in malignancies such as breast cancer, lymphomas, and multiple myeloma. Traditionally administered intravenously (IV), these biologic agents are increasingly being reformulated for subcutaneous (SC) delivery. The shift from IV to SC administration represents a meaningful advancement in patient-centered oncology care, offering comparable efficacy with enhanced convenience, improved healthcare efficiency, and potential cost benefits.

Monoclonal antibodies are laboratory-engineered immunoglobulins designed to bind specific antigens expressed on tumor cells or immune system components. Their mechanisms of action vary depending on the target. Some antibodies block growth factor receptors, others recruit immune effector cells through antibody-dependent cellular cytotoxicity (ADCC), and some activate complement-mediated destruction of malignant cells. Landmark agents such as Trastuzumab, targeting HER2-positive breast cancer, Rituximab, used in B-cell lymphomas, and Daratumumab, indicated for multiple myeloma, and the more recent pembrolizumab illustrate the profound clinical impact of this therapeutic class.

Historically, IV administration was considered necessary because monoclonal antibodies are large protein molecules with limited oral bioavailability. Intravenous infusion ensures complete systemic delivery and predictable pharmacokinetics. However, IV therapy has practical limitations. Infusions may last from one to several hours, particularly during initial cycles when infusion rates must be slow to reduce the risk of infusion-related reactions. Patients are required to attend specialized infusion centers, increasing time burden and healthcare resource utilization. In addition, venous access complications, infusion-related reactions, and prolonged chair time can negatively impact patient experience.

Subcutaneous administration has emerged as a viable alternative due to advancements in pharmaceutical formulation. A key development enabling SC delivery is the incorporation of recombinant human hyaluronidase, an enzyme that temporarily degrades hyaluronan in the extracellular matrix, allowing larger volumes of biologic agents to be absorbed through subcutaneous tissue. This innovation permits rapid injection of monoclonal antibodies that would otherwise require prolonged IV infusion.

Pharmacokinetically, SC administration differs from IV delivery. While IV administration provides immediate systemic exposure with 100% bioavailability, SC injections result in slower absorption through the lymphatic system. Peak plasma concentrations are generally lower with SC dosing, but total drug exposure (area under the curve, AUC) is carefully calibrated to achieve non-inferior therapeutic levels. Many SC formulations utilize fixed dosing rather than weight-based dosing, simplifying preparation and reducing medication errors.

Clinical trials comparing IV and SC formulations of trastuzumab, rituximab, and daratumumab have consistently demonstrated non-inferiority in efficacy outcomes such as progression-free survival, overall response rates, and overall survival. Importantly, safety profiles are comparable. While IV formulations are associated with systemic infusion-related reactions—especially during first administration—SC formulations tend to reduce these reactions but may increase mild local injection-site reactions such as erythema, swelling, or discomfort. Overall tolerability remains favorable.

One of the most significant advantages of SC administration is the reduction in treatment time. Whereas IV infusions may require hours of administration and observation, SC injections are often completed within minutes. This dramatically shortens clinic visits, improves patient convenience, and enhances quality of life—particularly for patients undergoing long-term maintenance therapy. The psychological burden of prolonged infusion sessions is also reduced.

From a healthcare systems perspective, SC administration improves operational efficiency. Shorter administration times free infusion chairs, reduce nursing workload per patient, and allow more patients to be treated within the same timeframe. During the COVID-19 pandemic, SC formulations proved especially valuable by minimizing patient exposure within hospital settings and reducing strain on healthcare infrastructure.

Despite these advantages, several considerations remain. Fixed dosing may not perfectly account for patients at extremes of body weight. Cold-chain storage requirements remain unchanged. Economic factors, including drug pricing and reimbursement policies, influence adoption across healthcare systems. Additionally, patient preference plays a central role; some individuals may still prefer IV administration due to familiarity or concerns about injection-site discomfort.

The transition from IV to SC monoclonal antibody therapy reflects a broader evolution toward patient-centered oncology care. Future directions include development of on-body delivery systems, expansion of home-based administration programs, and further innovation in biologic formulation technologies. As cancer treatment becomes increasingly personalized, optimizing the route of administration will remain an important component of comprehensive care strategies.

In conclusion, the shift from intravenous to subcutaneous administration of monoclonal antibodies in oncology represents a significant advancement in therapeutic delivery. By maintaining clinical efficacy while enhancing convenience and healthcare efficiency, SC formulations address both patient and system-level needs. As evidence continues to support their effectiveness and safety, subcutaneous monoclonal antibody therapy is poised to become an integral standard option in modern oncology practice.